Attralus
PrivateLast Round
Series B
Extension
Feb 6, 2024
Est. Valuation
$426M
Total Funding Raised
$197M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Attralus operates in Healthcare & Life Sciences and is based in Naples, Florida. Its latest recorded funding round was a Series B Extension round in February 2024.
Attralus is a biotechnology company that develops immunotherapies and imaging diagnostic platforms for the treatment of systemic amyloid diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Attralus Comparables
Compare Attralus with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prothena Corporation plc | 78% | |
| Paradox Immunotherapeutics | 77% | |
| Immutrin | 74% |
For institutional investors. Book with your work email.
Attralus Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Feb 6, 2024 | ||||
| Series B | Sep 8, 2021 | ||||
| Series A | Sep 14, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Attralus Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Surveyor Capital | Series B Extension, Series B |
| Janus Henderson Group | Series B |
| Logos Capital | Series B Extension, Series B |
| Citadel | Series B Extension, Series B |
| venBio | Series B Extension, Series B, Series A |
| Samsara BioCapital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 31% MoM.
- Feb 6, 2024
$56M round led by Alpha Wave Global
For institutional investors. Book with your work email.
Attralus Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Attralus's valuation, stock price, and market status.
Is Attralus a public or private company?
Attralus is a private company.
What is the current stock price of Attralus?
Attralus is a private company, so its shares have no public market price. Caplight tracks Attralus's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Attralus worth (valuation)?
Attralus's valuation is estimated at $426.0M based on funding round data.
Can I buy Attralus stock?
Attralus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Attralus's last funding round?
Attralus's most recent funding round was Series B Extension on February 6, 2024.
Who are the main investors in Attralus?
Key investors in Attralus include Logos Capital, venBio, Alpha Wave Global.
Will Attralus IPO soon?
No public IPO plans have been announced for Attralus.
How can I track Attralus secondary market activity?
Caplight tracks bids, offers, and trades in Attralus's shares on secondary markets.